MicroRNA-21 Knockout Exacerbates Angiotensin II-Induced Thoracic Aortic Aneurysm and Dissection in Mice With Abnormal Transforming Growth Factor--SMAD3 Signaling
MicroRNA-21 Knockout Exacerbates Angiotensin II-Induced Thoracic Aortic Aneurysm and Dissection in Mice With Abnormal Transforming Growth Factor--SMAD3 Signaling
复制标题
MicroRNA-21 敲除会加剧转化生长因子-βSMAD3 信号异常小鼠的血管紧张素 II 诱导的胸主动脉瘤和夹层
DOI:
10.1161/atvbaha.117.310694
复制
发表时间:
2018-05-01
影响因子:
8.7
通讯作者:
Xia, Jiahong
中科院分区:
文献类型:
--
作者:
Huang, Xiaofan;Yue, Zhang;Xia, Jiahong
Objective Thoracic aortic aneurysm and dissection (TAAD) are severe vascular conditions. Dysfunctional transforming growth factor- (TGF-) signaling in vascular smooth muscle cells and elevated angiotensin II (AngII) levels are implicated in the development of TAAD. In this study, we investigated whether these 2 factors lead to TAAD in a mouse model and explored the possibility of using microRNA-21 (miR-21) for the treatment of TAAD.Approach and Results TAAD was developed in Smad3 (mothers against decapentaplegic homolog 3) heterozygous (S3(+/-)) mice infused with AngII. We found that p-ERK (phosphorylated extracellular regulated protein kinases)- and p-JNK (phosphorylated c-Jun N-terminal kinase)-associated miR-21 was higher in TAAD lesions. We hypothesize that downregulation of miR-21 mitigate TAAD formation. However, Smad3(+/-):miR-21(-/-) (S3(+/-)21(-/-)) mice exhibited conspicuous TAAD formation after AngII infusion. The vascular wall was dilated, and aortic rupture occurred within 23 days during AngII infusion. We then examined canonical and noncanonical TGF- signaling and found that miR-21 knockout in S3(+/-) mice increased SMAD7 and suppressed canonical TGF- signaling. Vascular smooth muscle cells lacking TGF- signals tended to switch from a contractile to a synthetic phenotype. The silencing of Smad7 with lentivirus prevented AngII-induced TAAD formation in S3(+/-)21(-/-) mice.Conclusions Our study demonstrated that miR-21 knockout exacerbated AngII-induced TAAD formation in mice, which was associated with TGF- signaling dysfunction. Therapeutic strategies targeting TAAD should consider unexpected side effects associated with alterations in TGF- signaling.